Cover Image
市場調查報告書

中國的Montelukast市場分析

Investigation Report on China Montelukast Market, 2010-2019

出版商 China Research and Intelligence 商品編碼 296860
出版日期 內容資訊 英文 30 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
中國的Montelukast市場分析 Investigation Report on China Montelukast Market, 2010-2019
出版日期: 2015年05月28日 內容資訊: 英文 30 Pages
簡介

中國國內現在氣喘患者有3000萬人,過敏性鼻炎患者有3000∼4000萬人,還有隨著環境污染的惡化,患者數更為增加。Montelukast被認定是最適合的抗氣喘藥之一。從2005年的上市到2010年,國內Montelukast市場以年複合成長率(CAGR)45%的速度急速成長。競爭企業進入以後成長率下降了,不過儘管如此仍維持著年度10%的成長率,抱有巨大的潛在市場。

本報告提供中國的Montelukast市場相關分析、中國國內的產量及醫院用銷售額、價格趨勢(過去5年份)、各企業、各投藥形態的市場佔有率、主要製造商簡介、未來性的市場趨勢預測(今後5年份)等調查,並將其結果為您概述為以下內容。

第1章 Montelukast的相關概念

  • 定義
  • 症狀
  • 全球市場的銷售情形

第2章 中國的Montelukast市場概要

  • 專利現況
  • 主要製造商
  • 市場規模

第3章 Montelukast的銷售額分析

  • 銷售額
  • 銷售量

第4章 主要廠商的市場佔有率分析

  • 市場佔有率(以金額為準)
  • 市場佔有率(以數量為準)

第5章 各劑型的市場規模分析

  • 各劑型的市場佔有率(以金額為準)
  • 各劑型的市場佔有率(以數量為準)

第6章 Montelukast的醫院用標準價格(各企業)

  • Sichuan Xicheng Otsuka Pharmaceutical Co., Ltd.
  • Lunan Better Pharmaceutical Co., Ltd.
  • Merck & Co., Inc. (USA)
  • Merck Shark. Dohme, MSD(UK)

第7章 主要製造商分析

  • Sichuan Xicheng Otsuka Pharmaceutical Co., Ltd.
  • Lunan Better Pharmaceutical Co., Ltd.
  • Merck & Co., Inc. (USA)

第8章 中國的Montelukast市場未來展望

  • 市場規模的預測
  • 市場競爭的預測

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 1505182

More than 300 million people in the world suffer from seasonal asthma to different degrees. The situation is more serious in seriously polluted countries and regions where tobacco consumption is high. Asthma and allergic rhinitis are common diseases in today's world whose incidence has kept increasing every year due to nowadays' severe air pollution.

Montelukast, developed by Merck, has been widely applied to the treatment of allergic rhinitis and asthma. Montelukast, a selective cysteinyl leukotriene receptor D4 antagonist, selectively combines with leukotriene in the airway and blocks the action of anaphylactic mediator so as to improve respiratory inflammation and keep airway open.

In 1998, Montelukast sodium tablets (10mg) and chewable tablets (5mg) first came into America's market on FDA's approval with a trade name of Singulair. In 2000 and 2002, Montelukast chewable tablets (4mg) and Montelukast granules (4mg) were approved to enter the market successively for the prevention and long-term treatment of asthma of adults and children aged at 2 or above 2.

After Singulair's US patent expired on Aug.3, 2012, FDA has approved the generic drug applications of over 10 drug makers, among which Teva introduced tablets, chewable tablets and oral granules while Dr. Reddy's introduced tablets and chewable tablets.

In 1999, Montelukast chewable tablets (5mg) and tablets(10mg) came into Chinese market on approval with a trade name of Singulair. Later, Montelukast chewable tablets (4mg) and granules(4mg) came into Chinese market on approval successively. The generic drugs of Montelukast tablets (10mg) and chewable tablets(5mg) made by Sichuan Otsuka was approved to enter the market in 2006 with a trade name of Bystine. Besides, there are also many other companies declaring generic drug in Chinese market.

According to CRI's survey on some sample hospitals in China, the annual sales CAGR of Montelukast in Chinese hospitals exceeded 45% during the period of 2005-2010. With the appearance of some competitive products, the increase of Montelukast in Chinese market has slowed since 2011, but still remaining an annual growth of over 10%. Its sales CAGR still reached 25.5% during the period of 2010-2014.

It has been shown that China has more than 30 million asthma patients and 300-400 million patients suffering from allergic rhinitis. As the environmental pollution worsens in China, the number of patients will keep going up. In China, Montelukast is regarded as one of the most effective antiasthmatic drugs and therefore is estimated to enjoy huge market potential.

Readers can get at least the following information from this report:

  • incidence of respiratory ailments in China
  • Montelukast's price in Chinese hospitals
  • the production status of generic drugs of Montelukast in China
  • major Montelukast manufacturers and their market share in China
  • Market outlook of Montelukast in China

The author suggests the following groups of people purchase this report:

  • manufacturers of Montelukast APIs and finished medicines
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the Chinese market of Montelukast or other medicines, please contact CRI for customized research service

Table of Contents

1. Relevant Conceptions of Montelukast

  • 1.1. Definition
  • 1.2. Indication
  • 1.3. Sales in Global Market

2. Market Profile of Montelukast in China

  • 2.1. Patent Status
  • 2.2. Major Manufacturers
  • 2.3. Market Scale

3. Research of Montelukast Sales in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Regional Sales Value
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Regional Sales Volume

4. Research of Major Montelukast Manufacturers' Market Share in China

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Research of Dosage Forms of Montelukast in China

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Montelukast in Chinese Hospitals in 2014

  • 6.1. Sichuan Otsuka Pharmaceutical Co., Ltd.
  • 6.2. Lunan Pharmaceutical Co., Ltd.
  • 6.3. Merck. Co., Inc (USA)
  • 6.4. Merck Shark. Dohme, MSD(UK)

7. Major Manufacturers of Montelukast for Chinese Market in 2010-2014

  • 7.1. Sichuan Otsuka Pharmaceutical Co., Ltd.
  • 7.2. Lunan Pharmaceutical Co., Ltd.
  • 7.3. Merck Shark. Dohme, MSD

8. Market Outlook of Montelukast in China, 2015-2019

  • 8.1. Forecast of Market Scale
  • 8.2. Forecast of Competitive Landscape

Selected Charts

  • Chart Pharmaceutical Patent of Montelukast in China
  • Chart Sales Status of Montelukast in Chinese Market, 2010-2014
  • Chart Sales Value of Montelukast in China, 2010-2014 (unit in CNY million)
  • Chart Sales Value of Montelukast in Chinese Regions, 2010-2014 (unit in CNY million)
  • Chart Sales Volume of Montelukast in China, 2010-2014 (unit: million)
  • Chart Sales Volume of Montelukast in Chinese Regions, 2010-2014 (unit: million)
  • Chart Montelukast Manufacturers' Sales Value and Market Share in China, 2010-2014
  • Chart Sales Value and Market Share of Montelukast Made by Merck (UK) in China, 2010-2014
  • Chart Sales Value and Market Share of Montelukast Made by Sichuan Otsuka in China, 2010-2014
  • Chart Sales Value and Market Share of Montelukast Made by Lunan in China, 2010-2014
  • Chart Sales Value and Market Share of Montelukast Made by Merck (USA) in China, 2010-2014
  • Chart Market Share of Montelukast Manufacturers by Sales Volume, 2010-2014
  • Chart Montelukast Oral Granules' Sales Value and Market Share in China, 2010-2014
  • Chart Price of Montelukast Made by Sichuan Otsuka in Some Chinese Cities in 2014
  • Chart Price of Montelukast Made by Lunan in Some Chinese Cities in 2014
  • Chart Price of Montelukast Made by Merck (USA) in Some Chinese Cities in 2014
Back to Top